We found that the number and proportion of CD8+ T lymphocytes, CD8+TNFα+T lymphocytes and CD8+INFγ+ lymphocytes were significantly increased in tumor-bearing mice treated with fruquintinib or sintilimab alone or combination therapy (Figure 3A). This evidence concerns the gene CD8A and neoplasm.